Busulphan's Effect on Childhood Brain Tumors
Author Information
Author(s): Boland I, Vassal G, Morizet J, Terrier-Lacombe M-J, Valteau-Couanet D, Kalifa C, Hartmann O, Gouyette A
Primary Institution: Institut Gustave-Roussy
Hypothesis
The study evaluates the anti-tumour activity of busulfan as a single agent in paediatric solid tumour xenografts.
Conclusion
Busulphan showed significant anti-tumour activity in neuroblastoma and medulloblastoma xenografts at clinically achievable plasma drug concentrations.
Supporting Evidence
- Busulphan induced a significant tumour growth delay in neuroblastoma and medulloblastoma xenografts.
- At maximum tolerated doses, busulphan caused complete and partial tumour regressions.
- The pharmacokinetics of busulfan in mice were comparable to those in children receiving high-dose regimens.
Takeaway
Busulphan can help shrink certain childhood brain tumors when given in the right amounts.
Methodology
The study involved administering busulphan in different vehicles to evaluate its pharmacokinetics and toxicity, followed by therapeutic experiments in mice with tumor xenografts.
Limitations
The study did not evaluate the effectiveness of busulfan in all types of tumors, as it was inactive in a PNET xenograft.
Participant Demographics
The study used athymic mice to model pediatric solid tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website